Scinai Immunotherapeutics Ltd. Sponsored ADR
SCNI Healthcare Biotechnology
Scinai Immunotherapeutics Ltd. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $1.3 million, up 99.2% from fiscal 2024. In the quarter to June 2026, EPS grew 100.4% and free cash flow grew 51.1%, each against the same quarter a year earlier.
Follow SCNI
Scinai Immunotherapeutics Ltd. Sponsored ADR (SCNI) P/E ratio
As of 16 October 2026, Scinai Immunotherapeutics Ltd. Sponsored ADR (SCNI) trades at a P/E ratio of 0.0×. Over the past ten years it has ranged from 0.0× (March 2026) to 200× (October 2020); the current reading is higher than 89% of that period. That is below the Biotechnology industry median of 8.5× and below the Healthcare sector median of 23.0×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Mar 2026 | 0.1× | — |
| Mar 2025 | 0.0× | — |
| Sep 2024 | 0.0× | — |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CRIS Curis, Inc. compare | n/m |
| ZVSA ZyVersa Therapeutics, Inc. compare | n/m |
| BDRX Biodexa Pharmaceuticals PLC Unsponsored ADR compare | n/m |
| ATXI Avenue Therapeutics, Inc. compare | n/m |
| LYRA Lyra Therapeutics, Inc. compare | n/m |
| MNTRQ 9 Meters Biopharma, Inc. compare | n/m |
| BTTX Better Therapeutics, Inc. compare | n/m |
| SEELQ Seelos Therapeutics, Inc. compare | n/m |
| SCNI Scinai Immunotherapeutics Ltd. Sponsored ADR | 0.0× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)